Art

J-GLOBAL ID：202002263399596325   Reference number：20A2241784

Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19

COVID-19患者におけるサイトカインストームを治療するための塩酸ジャクチニブの可能性

Author (7)： Meng Xianmin (Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.) ,  Ling Yun (Department of Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.) ,  Zhang Li (Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.) ,  Zhang Qian (Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.) ,  Dong Ping (Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.) ,  Zhu Tongyu (Department of Urology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.) ,  Lu Hongzhou (Department of Infection and Imuunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.)
Material： BioScience Trends  (BST)
Volume： 14  Issue： 3  Page： 161-167(J-STAGE)  Publication year： 2020 
JST Material Number： L8367A  ISSN： 1881-7815  CODEN： BTIRCZ  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *coronavirus disease 2019 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2241784&from=J-GLOBAL&jstjournalNo=L8367A") }}

Author keywords (5)： severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,  coronavirus disease 2019 (COVID-19) ,  cytokines ,  jaktinib hydrochloride ,  feasibility

JST classification (2)： Treatment for infectious diseases,parasitic diseases.  (GD01030D) ,  Drug therapy(=pharmacotherapy)for respiratory system diseases  (GI05020J)

Reference (42)：

• 1. World Health Organization. Public Health Emergency of International Concern declared. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (accessed February 26, 2020).
• 2. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55:105924.
• 3. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020; 8:475-481.
• 4. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. doi: https://doi.org/10.1101/2020.02.06.20020974
• 5. Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020; https://doi.org/10.1101/2020.02.10.20021832

Terms in the title (6)： COVID-19 ,  患者 ,  サイトカインストーム ,  治療 ,  塩酸 ,  可能性